FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285229715> ?p ?o ?g. }

• W4285229715 endingPage "3393" @default.
• W4285229715 startingPage "3393" @default.
• W4285229715 abstract "Dear Sir, Over two years have passed since the first new coronavirus infections were discovered in China’s Wuhan province. Since then, efforts have concentrated on preventing and limiting transmission throughout the early phases of the epidemic. Global herd immunity studies in COVID-19 have shown an urgent need for effective COVID-19 vaccinations. The articles by Juyal et al. and Raina & Kumar on the COVID-19 immunization status in India caught our attention.[12] While the vaccination drive in India has indeed been one of the most incredible drives in history, the efficacy and effectiveness of the vaccines are still yet to be reported. Omicron, a novel SARS-CoV-2 variant of concern (VoC), was recently identified in South Africa.[3] The advent of the alpha, beta, and delta SARS-CoV-2 VoCs was linked to new waves of infections, spanning the entire globe, including India.[4] Because the emergence of new strains of this deadly virus is inevitable, dealing with the current pandemic while dealing with the added difficulties of emerging strains is a monumental task. Antibody therapies and vaccinations are among the last lines of defence against the growing COVID-19 pandemic. Mutations are insurmountable and will have an impact on vaccines and antibodies in development as well as those in use.[5] Although COVID-19 vaccinations are useful, none of them is fully successful in preventing COVID-19. A small percentage of the fully immunized population will still become ill with COVID-19 disease to variable degrees, more or less with the mutated strains. Although there are conflicting reports on whether COVID-19 vaccinations have consistently maintained high efficacy for each of the four VoCs preceding omicron, clinical trials have shown reduced efficacy for some vaccines in transmission circumstances where the beta variation is prominent. Previous variants reduced vaccine efficacy; for example, the ChAdOx 1 vaccine was 70% effective in preventing clinical infections in the UK for the D614G variant, whereas this efficiency dropped to 10% in South Africa for the beta variant.[6] The efficacy of the BNT162b2 vaccination in preventing clinical infections, on the other hand, was maintained across both the D614G and beta versions.[6] Because omicron contains a greater number of mutations than earlier VoCs, it is uncertain how it may affect the clinical efficiency of COVID-19 vaccines for mild disorders. After the introduction of the delta strain, a study conducted in India during the second wave of COVID-19 vaccinations demonstrated a considerable drop in the effectiveness of COVID-19 vaccines.[7] Aside from vaccination, cross-immunity across strains will be crucial in the future. Persons infected with SARS-CoV-2 who have pre-existing cross-reactive CD4+ memory T-cells are expected to have the following results when compared to infected individuals without such memory. When compared to persons without pre-existing cross-reactive cells, there is a reduction in the severity and duration of symptomatic/clinical illness.[8] A study conducted during the fourth wave of COVID-19 in Japan discovered that the cross-neutralizing activity of convalescent sera was protective against all variants except one. The significant neutralizing activity may produce a conformational shift in the virus’s spike protein, affecting immunological identification of the same. According to the findings of the study, those who recover from COVID-19 may be protected against the severity of infection with newer developing variations.[9] Another study’s findings suggest considerable decreases in cross-neutralization but not full effacement. These findings help us better comprehend the new SARS-CoV-2 mutations that are threatening to aggravate the COVID-19 pandemic.[10] Because T-cell immunity varies spatially and influences transmission, extrapolating epidemiological characteristics across populations may not be completely accurate. The existence of cross-immunity is thought to result in a milder course of illness and provide the host time to establish adaptive immunity to eliminate the virus. The presence of a significant number of asymptomatic or mild cases, a low infection-fatality ratio, and a fairly flat curve of proportion positivity of cases in proportion with total testing, both in phases of strict lockdown and step-wise unlocking, all point to the interplay of cross-immunity and herd immunity in the COVID-19 scenario in India. Cross-immunity seems to have resulted in a quicker formation of herd immunity.[11] In conclusion, we must maintain and expand our vaccine campaign because although it may not prevent infection, it can reduce the severity of illness. Vaccinations, in turn, provide herd immunity to the community, reducing the likelihood of a VoC outbreak. More study is needed to determine the efficacy of vaccination against VoCs. TWO Conclusive statements are needed. Ethical declaration Ethics approval is not required. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest." @default.
• W4285229715 created "2022-07-14" @default.
• W4285229715 creator A5022937457 @default.
• W4285229715 creator A5035782673 @default.
• W4285229715 creator A5056489991 @default.
• W4285229715 creator A5080975417 @default.
• W4285229715 date "2022-01-01" @default.
• W4285229715 modified "2023-09-25" @default.
• W4285229715 title "Omicron and other variants of SARS-CoV-2 roles of vaccines and herd immunity in protecting from the emerging strains" @default.
• W4285229715 cites W3091791643 @default.
• W4285229715 cites W3092675920 @default.
• W4285229715 cites W3127941442 @default.
• W4285229715 cites W3138447431 @default.
• W4285229715 cites W3155069380 @default.
• W4285229715 cites W3155537443 @default.
• W4285229715 cites W3171311320 @default.
• W4285229715 cites W3190566325 @default.
• W4285229715 cites W3192144393 @default.
• W4285229715 cites W4205698652 @default.
• W4285229715 doi "https://doi.org/10.4103/jfmpc.jfmpc_2372_21" @default.
• W4285229715 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36119258" @default.
• W4285229715 hasPublicationYear "2022" @default.
• W4285229715 type Work @default.
• W4285229715 citedByCount "2" @default.
• W4285229715 countsByYear W42852297152022 @default.
• W4285229715 crossrefType "journal-article" @default.
• W4285229715 hasAuthorship W4285229715A5022937457 @default.
• W4285229715 hasAuthorship W4285229715A5035782673 @default.
• W4285229715 hasAuthorship W4285229715A5056489991 @default.
• W4285229715 hasAuthorship W4285229715A5080975417 @default.
• W4285229715 hasBestOaLocation W42852297151 @default.
• W4285229715 hasConcept C106192422 @default.
• W4285229715 hasConcept C119599485 @default.
• W4285229715 hasConcept C127413603 @default.
• W4285229715 hasConcept C142724271 @default.
• W4285229715 hasConcept C159047783 @default.
• W4285229715 hasConcept C159654299 @default.
• W4285229715 hasConcept C188198153 @default.
• W4285229715 hasConcept C203014093 @default.
• W4285229715 hasConcept C22070199 @default.
• W4285229715 hasConcept C2779134260 @default.
• W4285229715 hasConcept C2779341262 @default.
• W4285229715 hasConcept C2780801004 @default.
• W4285229715 hasConcept C2908647359 @default.
• W4285229715 hasConcept C3008058167 @default.
• W4285229715 hasConcept C524204448 @default.
• W4285229715 hasConcept C71924100 @default.
• W4285229715 hasConcept C761482 @default.
• W4285229715 hasConcept C78519656 @default.
• W4285229715 hasConcept C8891405 @default.
• W4285229715 hasConcept C89623803 @default.
• W4285229715 hasConcept C99454951 @default.
• W4285229715 hasConceptScore W4285229715C106192422 @default.
• W4285229715 hasConceptScore W4285229715C119599485 @default.
• W4285229715 hasConceptScore W4285229715C127413603 @default.
• W4285229715 hasConceptScore W4285229715C142724271 @default.
• W4285229715 hasConceptScore W4285229715C159047783 @default.
• W4285229715 hasConceptScore W4285229715C159654299 @default.
• W4285229715 hasConceptScore W4285229715C188198153 @default.
• W4285229715 hasConceptScore W4285229715C203014093 @default.
• W4285229715 hasConceptScore W4285229715C22070199 @default.
• W4285229715 hasConceptScore W4285229715C2779134260 @default.
• W4285229715 hasConceptScore W4285229715C2779341262 @default.
• W4285229715 hasConceptScore W4285229715C2780801004 @default.
• W4285229715 hasConceptScore W4285229715C2908647359 @default.
• W4285229715 hasConceptScore W4285229715C3008058167 @default.
• W4285229715 hasConceptScore W4285229715C524204448 @default.
• W4285229715 hasConceptScore W4285229715C71924100 @default.
• W4285229715 hasConceptScore W4285229715C761482 @default.
• W4285229715 hasConceptScore W4285229715C78519656 @default.
• W4285229715 hasConceptScore W4285229715C8891405 @default.
• W4285229715 hasConceptScore W4285229715C89623803 @default.
• W4285229715 hasConceptScore W4285229715C99454951 @default.
• W4285229715 hasIssue "6" @default.
• W4285229715 hasLocation W42852297151 @default.
• W4285229715 hasLocation W42852297152 @default.
• W4285229715 hasLocation W42852297153 @default.
• W4285229715 hasOpenAccess W4285229715 @default.
• W4285229715 hasPrimaryLocation W42852297151 @default.
• W4285229715 hasRelatedWork W2022511384 @default.
• W4285229715 hasRelatedWork W2050951220 @default.
• W4285229715 hasRelatedWork W2127387725 @default.
• W4285229715 hasRelatedWork W2902213674 @default.
• W4285229715 hasRelatedWork W3082375889 @default.
• W4285229715 hasRelatedWork W3112312893 @default.
• W4285229715 hasRelatedWork W4205199251 @default.
• W4285229715 hasRelatedWork W4319444003 @default.
• W4285229715 hasRelatedWork W4319730151 @default.
• W4285229715 hasRelatedWork W979319891 @default.
• W4285229715 hasVolume "11" @default.
• W4285229715 isParatext "false" @default.
• W4285229715 isRetracted "false" @default.
• W4285229715 workType "article" @default.